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Abstract: 
Aspartate transaminase, a liver specific enzyme released into serum following acute liver injury is 
used in experimental organ preservation studies as a measure of liver IR injury. Whether post-
operative serum transaminases are a good indicator of IR injury and subsequent graft and patient 
survival in human liver transplantation remains controversial. 
Methods: 
A single centre prospectively collected liver transplant database was analysed for the period 1988-
2012. All patients were followed up for 5 years or until graft failure. Transaminase levels on the 1st, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
3rd and 7th post-operative days were correlated with the patient demographics, operative outcomes, 
post-operative complications and both graft and patient survival via a binary logistic regression 
analysis. 
Results: 
Graft and patient survival at 3 months was 80.3% and 87.5%. AST levels on the 3rd (p=0.005) and 7th 
(p=0.001) post-operative days correlated with early graft loss. Patients were grouped by their AST 
level (day 3): <107iU, 107-1213iU, 1213-2744iU and >2744iU. The incidence of graft loss at 3 
months was 10%, 12%. 27% and 59% and 1 year patient mortality was 12%, 14%, 27% and 62%. 
Conclusions: 
Day 3 AST levels correlate with patient and graft outcome post liver transplantation and would be a 
suitable surrogate end-point for clinical trials in liver transplantation. 
 
Introduction 
The recent widening of the listing criteria for liver transplantations has led to increased demand for 
organs and the implantation of more grafts from extended criteria donors. The use of grafts from 
donors following cardiac death (DCD) in the UK has increased from 6.9% in 2005(1) to 19.1% of 
grafts implanted in 2013(2). Grafts from extended criteria donors are more prone to ischaemia 
reperfusion (IR) injury and a poorer outcome following transplantation(3). Several donor and 
transplant variables have been reliably shown to reduce graft function and survival in multi-variate 
analyses including a long cold ischaemic time, donor hospital stay and elderly donors(4)(5)(1)(6). The 
use of DCD grafts in UK centres is associated with a 2 fold increase in recipient mortality and graft 
loss up to 3 years post transplantation(1). 
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As there is currently no accepted treatment for IR injury, strategies to ameliorate IR injury remain key 
research goals. Several strategies such as ischaemic preconditioning(7)(8), pharmacological 
preconditioning(9) and adoptive transfer of cells(10) can ameliorate IR injury in small animal models. 
Clinical translation of these strategies has been poor, partly due to a lack of understanding of the 
mechanisms of these strategies but also due to significant difficulty in funding trials large enough to 
show benefits to a single intervention in the complex circumstances of human liver transplantation. A 
key factor is that 90 day graft and patient survival are 89.3% and 90.8%(11) and hence powering trials 
with these as a primary end point is impossible due to trial size and cost. Surrogate end points (as in 
the use of creatinine clearance for kidney transplant outcomes) have not as yet been validated for liver 
transplant outcomes. 
NIH defines a surrogate endpoint as a biomarker intended to substitute for a clinical endpoint that 
should predict clinical benefit or harm or lack of both(12). Surrogate markers are biomarkers that 
reflect a pathological process at an earlier stage than death or significant illness. Surrogate markers 
are used routinely in cardiology trials(13) and trials in HIV(14)(15). 
Current endpoints in trials of liver transplantation include a reduction in total hospital stay, length of 
stay in intensive care, a reduction in post-operative co-morbidities and a reduction in post-operative 
serum transaminases(16)(17). None of these have been properly validated with graft specific outcome. 
Aspartate transaminase (AST) and Alanine transaminase (ALT) are intracellular liver enzymes that 
are released into the circulation in high quantities following hepatocyte injury. 
A reduction in serum AST and ALT levels at 48 hours has been used as a primary endpoint for liver 
IR studies in small animal models(8)(10)(18). 
Serum transaminases are monitored daily in patients following liver transplantation as a marker of IR 
injury. Serum transaminases are released from damaged hepatocytes however the use of peak 
transaminase levels to predict outcome following liver transplantation is controversial. 
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A small number of analyses have correlated peak transaminase levels with early graft failure 
specifically primary graft non-function (PGNF) and late complications in DCD grafts. They have 
demonstrated that peak AST levels of >2000iU(19), 3500iU(20) or even 5000iU(21) can accurately 
predict PGNF. The development of non-anastomotic biliary strictures in DCD grafts is associated 
with higher peak ALT and AST levels(22). United Network for Organ Sharing (UNOS) currently 
incorporate a peak AST value of greater than 3000iU when describing PGNF and when deciding to 
relist a patient for transplantation. Although higher AST levels have been shown to correlate with IR 
injury on post reperfusion biopsies, there was significant overlap between grafts that functioned and 
those failed(23). Although these studies demonstrate that peak AST levels correlate with PGNF and 
graft loss within 7 days there are several limitations to current data. Peak AST levels can happen at 
different time-points following transplantation and make it difficult to draw comparisons between 
patients. Secondly these studies have identified the prognostic significance of only excessive post-
operative AST levels that are not experienced in the majority of patients. Furthermore the majority of 
these studies have correlated AST levels with the development of primary graft non-function within 7 
days. Although a devastating complication following liver transplantation, PGNF accounts for a small 
proportion of graft loss and post-operative morbidity. The use of an endpoint in clinical trials must 
correlate with a more global prognosis to be of any significance and would ideally be measured at a 
specific time-point to allow reproducibility. 
The aim of this study was to identify a reliable surrogate end point for clinical trials in liver 
transplantation. 
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Methods 
A prospectively collected transplant database was reviewed for the period 1988 to 2012 to allow an 
adequate sample size and adequate follow up data. All donor types (DBD, DCD, split and domino 
grafts) were included in the analysis. Re-transplantations were also included. 
AST, ALT and bilirubin levels were measured in peripheral venous blood (Clinical Chemistry 
analyser, Modular analytics P module, Roche, Indianapolis) daily in the post-operative period. 
 
Total graft loss: 
Total graft loss was accepted as a graft lost for any reason following transplantation. Date of graft loss 
was accepted as date of death or date of re-transplantation. Grafts lost within the first 3 months were 
defined as early graft loss and those lost after 3 months were defined as late graft loss. 
A further analysis was performed between the years of 1998 and 2012 – this included less grafts but 
was to ensure that transaminase values as a surrogate marker was valid in a modern cohort. 
 
Liver specific graft loss following transplantation: 
Liver specific graft loss was defined as a graft lost secondary to specific intra hepatic pathology and 
included graft loss due to primary graft non-function, non-thrombotic infarction, acute rejection, 
ductopenic rejection and biliary complications (excluding anastamotic stricture or bile leak). Hepatic 
artery thrombosis and portal vein thrombosis were excluded as a cause of graft loss from the analysis 
as it would be difficult to rule out a technical failure as contributing to graft loss under these 
circumstances.  
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Date of graft loss was accepted as date of death or date of re-transplantation. 
Grafts lost within the first 3 months following liver transplantation were defined as early graft loss 
and those lost after 3 months were defined as late graft loss. 
 
Clinical outcomes: 
A ROC curve was performed to identify specificity and sensitivity of AST day 3 values at predicting 
liver specific graft loss. A likelihood ratio was calculated for specific AST values. Patients were 
grouped according to their AST values on the 3rd post-operative day and the percentage of total graft 
loss, liver specific graft loss at 3 months and percentage mortality at 30 days, 90 days and 1 year were 
measured along with mean number of days in ITU, mean number of days ventilated, percentage of 
patients requiring transient renal support (haemofiltration and haemodialysis) – patients with 
creatinine values of greater than 150micromol/L were removed from this analysis to avoid the bias of 
pre-existing renal impairment - and the percentage of patients that developed a bacteraemia or a site 
specific infection (chest, wound and intra-abdominal). Infective complications were only accepted 
after a positive microbiology culture. 
 
Statistical analysis: 
Results were analysed on the Statistical Package for the Social Sciences (SPSS) version 21, IBM. 
Transaminase levels were correlated with both short-term (3 month) and long-term (5 year) outcome. 
Transaminase levels were adjusted for cold ischaemic time, secondary warm ischaemic time, donor 
and recipient age, recipient gender and pre-operative MELD score using a binary logistic regression 
analysis. 
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When statistical analyses were performed to analyse transaminase levels with long term graft loss, 
grafts that had been lost in the first 3 months post transplant were excluded from the analysis. 
Patients with missing data were excluded from the analysis. 
Binary logistic and linear regression models and a ROC curve were performed to analyse 
transaminase levels.  
A p value of <0.05 was considered to be significant. 
 
Results: 
Data was analysed on 1272 patients (640 Male/628 Female/4 Unspecified) undergoing liver 
transplantation at the Royal Free Hospital, London between 1988 and 2012. Minimum follow up was 
3 months or until graft failure. 181 patients were excluded due to missing data. The mean donor age 
was 42 (range 6-78). The majority of grafts were from donors after brain death (DBD) (97%). The 
mean cold ischaemic time was 604 mins (range 42-1194). 99% of grafts were preserved in 
commercial University of Wisconsin preservation fluid (Organ Recovery Systems, Chicago). Further 
donor details are provided in Table 1. The mean recipient age at time of transplantation was 47 years 
(range 37-69) and the mean pre-operative MELD score was 18 (Range 3-40) Further recipient 
characteristics are given in Table 2. The main indications for transplantation were hepatitis C virus 
(HCV) related cirrhosis (22%) and alcoholic liver disease (ALD) (17%). Other indications are given 
in Table 3. 
The median AST levels peaked on the first post-operative day (Table 4). 
206 grafts (18.9%) were lost in the first 3 months. A further 221 grafts (20.3%) were lost between 3 
months and 5 years. The incidence of pathology encountered is in Table 5. 
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Transaminase levels and early total graft failure (0-3 months): 
For this analysis 1062 grafts were analysed. AST levels on the 1st post-operative day were 
significantly higher in grafts that were lost within 3 months than those that were still functioning 
(p=0.013). On the 3rd post-operative day, AST levels (p<0.001) and ALT levels (p<0.001) were 
significantly higher in grafts that were lost than those that were still functioning after 3 months. 
A binary logistic regression model showed that AST levels on the 3rd post-operative day (p=0.002) 
and that AST levels (p<0.001) and ALT levels (p=0.006) on the 7th post-operative day were strong 
predictors of graft loss. Transaminase levels on the 1st post-operative day were not indicative of early 
graft loss (AST p=0.645, ALT p=0.363). Although AST levels on the 3rd post-operative day correlated 
strongly with early graft failure, ALT levels did not (p=0.710) (Table 6). 
The binary logistic regression analysis was rerun including only transplants performed between the 
years of 1998 and 2012. 796 grafts were included in this analysis. AST levels on the 3rd post-operative 
day (p=0.003) but not ALT levels on the 3rd post-operative day (p=0.548) correlated with early graft 
loss in this recent but reduced size cohort. 
  
Transaminase levels and early liver specific graft failure (0 and 3 months): 
For this analysis, 151 grafts that failed within 3 months for a non-liver specific reason were excluded. 
940 grafts were therefore included in this analysis. AST levels on the 1st post-operative day were 
significantly higher in grafts that failed within three months than grafts that survived (p=0.024) three 
months or more. On the 3rd post-operative day, AST levels (p<0.001) and ALT levels (p=0.025) were 
significantly higher in grafts that failed than those that survived more than three months. 
A binary logistic regression model showed that AST levels on the 3rd post-operative day (p=0.005) 
and 7th post-operative day were strong predictors of early graft failure (p=0.001). Transaminase levels 
on the 1st post-operative day were not indicative of early graft loss (AST p=0.092, ALT p=0.962). 
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Although AST levels on the 3rd postoperative day correlated strongly with early graft failure, ALT 
levels did not (p=0.966). 
 
AST/ALT levels and late graft failure (3 months to 5 years): 
623 graft outcomes were analysed. There was no correlation between AST and ALT levels on day 3 
and graft lost between 3 months and 5 years post transplant. (Table 6) 
 
AST on the 3rd post-operative day and clinical outcome measures: 
Having identified AST levels on the 3rd post-operative day as the earliest transaminases to correlate 
with early graft loss, a ROC curve was performed to identify the AST level on the 3rd post-operative 
day at which the risk of developing liver specific graft failure at 3 months became significant as it 
yielded a stronger AUC than total graft loss (Fig 1). The area under the curve was 0.739 (0.663-0.814) 
with a p value of <0.001. An AST of below 106.5iU was identified as the best fit to predict graft 
survival with a negative likelihood ratio of 0.13 and negative predictive valve of 99.45%. An AST 
level of above 2744.5iU was identified as the best fit to predict graft failure with a positive likelihood 
ratio of 13.1 and a positive predictive value of 34.62%. To prove that it is not only extreme values that 
correlate with graft failure, the central group was further divided. An AST level of 1213iU was 
chosen as the positive likelihood ratio of this value was 4.1 identifying it as a moderate predictor of 
graft failure. 
Patients were divided into 4 groups according to day 3 AST values (<107iU, 107-1213iU, 1213-
2744iU and >2744iU). 
In grafts with AST levels of <107iU (n=201), the incidence of graft loss at 3 months was 9.6% and 1 
year mortality was 12.2%. In grafts with AST levels of between 107 and 1213iU (n=883), the 
incidence of graft loss at 3 months was 12.2% and 1 year mortality was 14.4%. In grafts with AST 
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levels of between 1213 and 2744iU (n=97), the incidence of graft loss at 3 months was 25.8% and 1 
year mortality was 26.4%. In grafts with AST levels above 2744iU (n=40), the incidence of graft loss 
at 3 months was 57.5% and 1 year mortality was 61.1%. This incremental increase among the groups 
was also observed in liver specific graft loss at 3 months, 30 and 90 day mortality (table 7). 
The need for organ support and length of stay in ITU similarly increased among the groups. The 
incidence of renal replacement therapy (RRT) in the group of patients with an AST of less than 107iU 
was 13.3% and in the group of patients with AST levels of greater than 2744iU was 58.8% (table 7). 
There was a greater incidence of proven bacteraemias and site-specific infective complications in the 
groups of patients with higher AST levels (table 7). 
 
The effect of donor and transplant variables on day 3 AST levels. 
Having identified AST on the 3rd post-operative day as correlating with post transplant outcomes, 
linear regression models were performed to assess the impact of donor and transplant variables on 
AST levels on the 3rd post-operative day. Length of cold ischaemic time (p=0.041) and time taken to 
perform the vascular anastomoses (secondary warm ischaemia) (p<0.001) correlated with AST levels 
on the 3rd post-operative day while older age of donor (p=0.705) and length of donor time spent in 
ITU (p=0.317) did not. Type of graft (DBD/DCD/split/domino) inserted did not correlate with AST 
levels on the 3rd post-operative day (p=0.200). 
 
The effect of recipient variables on day 3 AST levels. 
Higher pre-operative MELD scores correlated with increased AST levels on the 3rd post-operative day 
(p=0.042). No other recipient variable correlated with AST levels on the 3rd post-operative day 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Discussion: 
Using a large single centre prospective liver transplant database, serum AST and ALT levels within 
the first post-operative week were correlated with post-operative recovery and both short and long 
term graft and patient outcomes. AST levels on the 3rd post operative day were found to closely 
correlate with the rate of post-operative complications and short-term graft and patient survival. A 
simple scale for grouping day 3 AST levels was found to correlate well with post transplant outcomes 
and could be adopted as a surrogate end-point for short-term graft and patient survival in clinical trials 
of liver transplantation. 
An audit performed by the Royal College of Surgeons of England in November 2012 found that 
between 1994 and 2012, 7953 elective liver transplants were performed in the UK with a 90 day graft 
loss of 10.7% and a 5 year graft loss of 29.5%. Our centre has a 90 day graft loss of 13.1% and a 5 
year graft loss of 31.2%. This data is therefore representative of liver transplantation outcomes in the 
UK and hence this analysis of the prognostic significance of day 3 AST levels is likely to be widely 
applicable. 
Previous studies have correlated peak AST levels with outcome post liver transplantation and found 
that peak AST levels correlate with the diagnosis of primary graft non-function and graft loss within 7 
days. However, this is the first study to identify the post-operative day on which the AST level is most 
predictive of outcome. AST levels on the 3rd post-operative day most accurately predict post-operative 
morbidity and mortality. 
This analysis shows that higher AST levels in the early post transplant period correlate with the short 
term (<3 months) but not the long term (>3 months) graft and patient survival suggesting that early 
graft damage is amenable to recovery. In a recent study (22) high peak transaminases were found to 
predict the incidence of non-anastomotic strictures (biliary complications) in DCD grafts but had no 
correlation with outcome in DBD grafts. This finding is backed up by these results as 97% of grafts 
analysed were DBD grafts and AST levels did not correlate with long-term graft loss. 
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It is interesting that although ALT levels on the third post-operative day were significantly higher in 
grafts that failed within 3 months than those that were still functioning, when analysed in the 
regression analysis, ALT levels were not significant until the 7th post-operative day. This may reflect 
the fact that although ALT is more liver-specific than ALT, there is more AST contained in the liver 
than ALT(24). Our results show that median peak AST levels were higher than median peak ALT 
levels (651iU vs 452iU). Furthermore serum AST levels reduce more rapidly than serum ALT 
levels(24). In this analysis median AST levels had dropped to 272iU by day three while serum ALT 
levels remained elevated at 425iU and by day 7 serum ALT levels correlated with outcome. This 
pattern of transaminase reduction is mirrored in other studies(25) and may explain why serum AST 
levels are a better marker in early identification of a healthy graft without ongoing damage. 
 
A ROC curve demonstrated that the AST value on the 3rd post-operative day was a moderate predictor 
of liver specific graft failure with an AUC of 0.739 (0.663-0.814). Using likelihood values an AST 
level of below 106.5iU on day 3 was identified as the strongest predictor of graft survival with a NPV 
of 99.45% and an AST level of greater than 2744 iU as the best predictor of graft failure with a PPV 
of 34.62%. Day 3 AST levels of below 106.5iU are associated with a 10% risk of graft loss from all 
causes and a 6% risk of mortality within 3 months. AST levels of greater than 2744iU are associated 
with a 59% risk of graft loss and 49% risk of mortality within 3 months. Patients with AST levels 
above 2744iU are also at significantly increased risk of end organ failure and infective complications. 
These are post transplant complications associated with graft preservation and IR injury and the 
resulting poor initial graft function. The high incidence of these complications in patients with high 
day 3 AST levels supports the use of day 3 AST levels as a clinically relevant surrogate endpoint of 
outcome in clinical trials in liver transplantation. 
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To obtain sufficient data to analyse graft and patient survival in a single centre study,, required a long 
time period to be analysed, which could be viewed as a limitation of this study. During this time 
period some practices in liver transplantation have changed including immunosuppression protocols, 
retrieval and implantation techniques and transfusion practices. However the time duration is also 
beneficial in that it allows AST levels to be analysed over a period of changing practise and suggests 
that changes over time do not alter the importance of the day 3 AST and its correlation with graft and 
patient survival. A subgroup analysis of AST levels in transplants performed only between 1998 and 
2012 demonstrated that AST levels on the 3rd post-operative day remain significantly correlated with 
graft loss. 
 
In this study, the most significant donor and transplant factors to result in raised AST levels on the 3rd 
day post-op were a prolonged cold ischaemic time and a longer duration of vascular reconstruction 
(secondary warm ischaemia) suggesting that the ischaemic damage is a key determinant of short term 
graft and patient survival.  The length of ischaemic time correlates more strongly with peak AST 
levels on the 1st rather than on the 3rd post-operative day. This would suggest that day 3 AST levels 
are a reflection of the graft’s ability to recover from cold or warm ischaemia. It is well documented 
that length of cold ischaemic time correlates with outcome post transplantation and this is in keeping 
with our results. Cold ischaemic time however was not the only factor that correlated with outcome. 
The length of time taken to perform the vascular anastomoses or secondary warm ischaemic time 
significantly correlated with AST levels and graft loss.  To our knowledge only a limited number of 
studies have investigated the length of time taken to perform the vascular anastomosis with outcome 
in renal transplantation and found that longer anastomotic time correlates with a poorer 
outcome(26)(27). It is unclear if this finding reflects and more difficult implantation period and 
increased likelihood of HAT and PVT or increased graft damage occurring during secondary warm 
ischaemia. It is likely a combination of all three factors but further work is needed to clarify this. 
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Interestingly although the use of a DCD graft correlated with increased peak AST levels on day 1, it 
was not an independent predictor of raised AST levels on the 3rd post-operative day. This may reflect 
the fact that the study period ended at a time period when the use of DCD grafts was limited (only 33 
DCD grafts were in this study) and the donor criteria for use of DCD grafts was very restricted. 
Although both the donor risk index (DRI) and the EuroTransplant Donor Risk Index (ETDRI) identify 
donor age as an independent risk factor for early graft loss(6)(28), in this cohort, donor age had no 
correlation with early graft loss. This may reflect the fact that the average cold ischaemic time in this 
current UK patient cohort (604mins) is significantly longer than in the cohort originally used to 
describe the DRI (493 mins) and slightly longer than the cold ischaemic time in the ET-DRI cohort 
(582mins). This will alter the impact of age and other variables on graft outcome as cold ischaemic 
time is the one of the strongest predictors of early graft failure and raised post-operative 
transaminases. Furthermore it is unclear if length of anastomotic time was included in these analyses 
which will influence the results. 
Surrogate markers are routinely used in other medical disciplines to evaluate the risk/benefit of new 
treatment modalities. Surrogate markers need to reflect the underlying disease process and to provide 
an early indication of clinical benefit or harm(29). This analysis identifies AST levels on day 3 as an 
effective surrogate marker of outcome following liver transplantation that could be used as a suitable 
endpoint in trials of liver transplantation. 
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Table 1: Donor characteristics 
 
Values given are median and range 
 
Age 43 (6-78) 
Type of Donor Deceased brain death 1228 
Deceased cardiac death 33 
Domino 8 
Split 3 
Number of grafts analysed at 
each time point 
0-3 months 1062 
3months-5 years 623 
Length of time in ITU 3 (0-185) 
Cold ischaemic time (minutes) 604 (42-1194) 
Implantation warm ischaemic time (minutes) 43 (19-220) 
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Table 2: Recipient characteristics 
Gender Male 640 
Female 628 
Unspecified 4 
Age 50 (2-69) 
Length of time in ITU 3 (0-148) 
Pre operative MELD score 16 (3-40) 
Pre-operative creatinine (micromoles/L) 85 (16-753) 
Preoperative haemoglobin (g/dL) 11 (5.4-17.0) 
Values given are median and range 
 
Table 3: Indication for transplantation 
 
Indication for transplantation number percentage 
Hepatitis C Cirrhosis 280 22.0% 
Alcohol Liver Disease 221 17.4% 
Primary Biliary Cirrhosis 149 11.7% 
Hepatitis B Cirrhosis 114 9.0% 
Primary Sclerosing Cholangitis 109 8.6% 
Acute Liver Failure (unknown cause) 69 5.4% 
Cryptogenic Cirrhosis 62 4.9% 
Hepatic Artery Thrombosis 39 3.1% 
Auto-immune Hepatitis 34 2.7% 
Metabolic Diseases 24 1.9% 
Acute Liver Failure (paracetamol) 23 1.8% 
Wilson’s Disease 20 1.6% 
Primary Graft Non-Function 20 1.6% 
Other 20 1.6% 
Biliary Complication 16 1.3% 
Chronic Rejection 13 1.0% 
Budd Chiari Syndrome 12 0.9% 
Familial Adenomatous Polyposis 11 0.9% 
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Table 4: AST levels on the 1st, 3rd and 7th post-operative day. 
 
Table 5: Pathology and period of liver specific graft failure. 
Pathology of graft failure 1-3 months 3 months – 5 years 
Extra-hepatic cause 95 157 
Vascular occlusion 56 5 
Non-thrombotic infarction 23 2 
Primary graft non-function 23 0 
Acute rejection 1 0 
Chronic rejection 3 25 
Ductopenic rejection 0 14 
Biliary complications 4 16 
Others 1 2 
 
Hepato-Cellular Carcinoma (non-
cirrhtoic) 
8 0.6% 
Other Malignancy 8 0.6% 
Non-Thrombotic Infarction 6 0.5% 
Ductopenic Rejection 3 0.2% 
Polycystic Disease 1 0.1% 
Biliary Atresia 1 0.1% 
 Day 1 Day 3 Day 7 
Mean (IU) 1006 614 120 
Median (IU) 651 272 61 
Std Deviation 1560 1215 248 
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Table 6: Binary logistic regression model showing correlation between day 3 AST levels(*) and early 
but not late graft loss  
 Grafts lost 0 - 3 months Grafts lost 3 months - 5 years 
MELD .000 .903 
AST day 1 .634 .935 
ALT day 1 .351 .468 
AST day 3 .002* .703* 
ALT day 3 .622 .804 
AST day 7 <.001 .402 
ALT day 7 .005 .901 
Rec gender .137 .657 
Rec age .732 .965 
Don age .447 .287 
CIT .014 .625 
Reperfusion Time .434 .243 
 
 
Table 7: Grouped AST levels (iU) on the 3rd post-operative day and incidence of clinical morbidity and 
mortality 
AST levels (iU) <107 107-1213 1213-2744 >2744 
No.in group 201 882 98 41 
Liver specific graft loss 0.5% 3.2% 7.7% 34.6% 
Total graft loss 10% 13.7% 26.5% 58.5% 
30 day mortality 3.5% 5.1% 15.3% 34.1% 
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90 day mortality 5.5% 8.2% 18.4% 48.8% 
1 year mortality 12.2% 12.4% 27.2% 62.2% 
Days in ITU (mean) 7 7 9 15 
Days ventilated (mean) 5 6 8 14 
Need for renal support 13.3% 12.4% 23.8% 57.1% 
Bacteraemia 0.5% 4.9% 16.3% 12.5% 
Intra-abdominal infection 1% 3.2% 16.3% 17.5% 
Chest infection 1% 4.7% 14.3% 10% 
Wound infection 0.5% 8.4% 24.5% 27.5% 
 
Figure 1: ROC curve of AST levels on the 3rd post-operative day against liver specific graft loss at 3 months.  
AUC 0.739 95% CI -0.663-0.814 
 
 
 
